Cerebral Amyloid Angiopathy
Conditions
Brief summary
Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients.
Detailed description
Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients. It is expected that this will be systematically evaluated through a multi-center, randomized, double-blind, mimic-controlled clinical trial.The effectiveness and safety of the protocol in reducing the incidence of vascular events were observed, and its impact on patients' cognitive function and neurological function was also examined. The research plan includes patients with CAA-related intracranial hemorrhage within 7 days of onset.The therapeutic effect was measured by indicators such as the proportion of vascular events in patients at different stages of the disease, including hematoma expansion rate and abnormal liver and kidney functions.The safety was evaluated based on the incidence rate, and the anti-inflammatory, antioxidant and other properties of traditional Chinese medicine prescriptions were explored with the aid of imaging and biological indicators.The mechanism for improving cerebrovascular function. It is expected that through this study, it will provide clinical treatment for patients with CAA-related intracranial hemorrhage.A brand-new and effective plan brings better prognosis to patients, reduces the medical burden on patients' families and lowers the social burden medical costs. At the same time, it will also provide important reference basis for subsequent related research and promote the integrated treatment of traditional Chinese and Western medicine.
Interventions
DRUGJiedu Huayu Oral Prescription
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated with Cerebral Amyloid Angiopathy
DRUGPlacebo
A placebo similar to the Jiedu Huayu Oral Prescription
Sponsors
Beijing Tiantan Hospital
Dongzhimen Hospital, Beijing
The First Hospital of Jilin University
Huairou Hospital of Traditional Chinese Medicine
Weihai Wendeng District Central Hospital
Nanyang First People's Hospital of Henan province
Luohe Central Hospital
Baofeng County People's Hospital
Taoyuan County People's Hospital
Qingdao Huangdao District Central Hospital
Guantao County People's Hospital
Lushan County Hospital of Traditional Chinese Medicine
Yutian County Hospital of Traditional Chinese Medicine
Xianghe County Hospital of Traditional Chinese Medicine
Wuyuan County People's Hospital
Jiyuan Hospital of Traditional Chinese Medicine
Tonghua People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* ① Possible or very likely CAA-ICH; * Within 7 days of onset; ③ Primary supratentorial intracerebral hemorrhage (bleeding volume ≤40ml); * GCS≥8 points; * NIHSS score ≤25 points; ⑥50≤age≤90 years old; ⑦ Gender is not limited; ⑧ The subject or their legal representative gives informed consent and signs the informed consent form.
Exclusion criteria
* Those who are known to be allergic to the components of the traditional Chinese medicine compound used in the experiment; * It is known that after treatment with vascular malformations, aneurysms, coagulation disorders, anticoagulant or antiplatelet drugs, Intracranial conditions caused by clear etiologies such as thrombolytic therapy, post-infarction hemorrhage transformation, hematological diseases, moyamoya disease, etc; * Patients with traumatic intracranial hemorrhage; * Patients with active peptic ulcers or other clear tendencies of rebleeding; * Patients with severe liver or kidney dysfunction (Note: Severe liver dysfunction is defined as ALT or AST being greater than. ⑥ Those who have received or are planning to undergo surgical treatment; ⑦ Those who suffer from other life-threatening serious diseases and have an expected survival time of less than six months; ⑧ Other conditions that significantly limit the evaluation of neurological function, prevent the completion of cranial magnetic resonance imaging, or affect the follow-up of patient; ⑨ Pregnant women, those planning to become pregnant or lactating women; ⑩Those who are currently participating in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vascular events | 180 days after onset | Incidence of vascular events, including hemorrhagic and ischemic vascular events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Vascular Events at 30 Days | 30 days after onset | Incidence of vascular events. |
| Incidence of Vascular Events at 90 Days | 90 days after onset | Incidence of vascular events. |
| Incidence of Vascular Events at 1 Year | 1 year after onset | Incidence of vascular events. |
| Changes in Neurocognitive Function | 180 days after onset | Changes in neurocognitive function assessed by TICS-M, MMSE, and MOCA scales. |
| Neurological Function Recovery at 30 Days | 30 days after onset | Neurological function recovery evaluated by mRS score. |
| Neurological Function Recovery at 90 Days | 90 days after onset | Neurological function recovery evaluated by mRS score. |
| Neurological Function Recovery at 180 Days | 180 days after onset | Neurological function recovery evaluated by mRS score. |
| Neurological Function Recovery at 1 Year | 1 year after onset | Neurological function recovery evaluated by mRS score. |
| Changes in Quality of Life at 30 Days | 30 days after onset | Changes in quality of life assessed by SF-36 and EQ-5D scales. |
| Changes in Quality of Life at 90 Days | 90 days after onset | Changes in quality of life assessed by SF-36 and EQ-5D scales. |
| Changes in Quality of Life at 180 Days | 180 days after onset | Changes in quality of life assessed by SF-36 and EQ-5D scales. |
| Changes in Quality of Life at 1 Year | 1 year after discharge | Changes in quality of life assessed by SF-36 and EQ-5D scales. |
Countries
China
Contacts
CONTACTDandan Wang Wang
Outcome results
None listed